Biomerica, Inc. (BMRA)
NASDAQ: BMRA · Real-Time Price · USD
2.520
+0.070 (2.86%)
At close: Dec 31, 2025, 4:00 PM EST
2.470
-0.050 (-1.98%)
After-hours: Dec 31, 2025, 7:19 PM EST
Biomerica Revenue
Biomerica had revenue of $1.38M in the quarter ending August 31, 2025, a decrease of -23.63%. This brings the company's revenue in the last twelve months to $4.88M, down -11.31% year-over-year. In the fiscal year ending May 31, 2025, Biomerica had annual revenue of $5.31M, down -1.92%.
Revenue (ttm)
$4.88M
Revenue Growth
-11.31%
P/S Ratio
1.25
Revenue / Employee
$90,444
Employees
54
Market Cap
7.43M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 5.31M | -104.00K | -1.92% |
| May 31, 2024 | 5.42M | 76.00K | 1.42% |
| May 31, 2023 | 5.34M | -13.53M | -71.71% |
| May 31, 2022 | 18.87M | 11.67M | 162.13% |
| May 31, 2021 | 7.20M | 506.32K | 7.57% |
| May 31, 2020 | 6.69M | 1.49M | 28.69% |
| May 31, 2019 | 5.20M | -363.50K | -6.53% |
| May 31, 2018 | 5.56M | -227.49K | -3.93% |
| May 31, 2017 | 5.79M | 651.85K | 12.68% |
| May 31, 2016 | 5.14M | 177.44K | 3.58% |
| May 31, 2015 | 4.96M | -158.08K | -3.09% |
| May 31, 2014 | 5.12M | -1.35M | -20.89% |
| May 31, 2013 | 6.47M | 391.83K | 6.44% |
| May 31, 2012 | 6.08M | 1.18M | 24.12% |
| May 31, 2011 | 4.90M | -175.85K | -3.46% |
| May 31, 2010 | 5.08M | 140.45K | 2.85% |
| May 31, 2009 | 4.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BMRA News
- 9 days ago - Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test - GlobeNewsWire
- 21 days ago - Egyptian Drug Authority Authorizes Biomerica's Complete Screening Test Portfolio - GlobeNewsWire
- 5 weeks ago - Biomerica's inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS - GlobeNewsWire
- 2 months ago - Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand - GlobeNewsWire
- 2 months ago - Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica's inFoods® IBS Test in the U.S. - GlobeNewsWire
- 2 months ago - Biomerica Reports First Quarter Fiscal 2026 Financial Results - GlobeNewsWire
- 3 months ago - Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors - GlobeNewsWire
- 4 months ago - Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes - GlobeNewsWire